Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion
Open Access
- 15 August 2010
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (16), 8132-8140
- https://doi.org/10.1128/jvi.02699-09
Abstract
Respiratory syncytial virus (RSV) is a major cause of virus-induced respiratory disease and hospitalization in infants. Palivizumab, an RSV-neutralizing monoclonal antibody, is used clinically to prevent serious RSV-related respiratory disease in high-risk infants. Motavizumab, an affinity-optimized version of palivizumab, was developed to improve protection against RSV. These antibodies bind RSV F protein, which plays a role in virus attachment and mediates fusion. Determining how these antibodies neutralize RSV is important to help guide development of new antibody drugs against RSV and, potentially, other viruses. This study aims to uncover the mechanism(s) by which palivizumab and motavizumab neutralize RSV. Assays were developed to test the effects of these antibodies at distinct steps during RSV replication. Pretreatment of virus with palivizumab or motavizumab did not inhibit virus attachment or the ability of F protein to interact with the target cell membrane. However, pretreatment of virus with either of these antibodies resulted in the absence of detectable viral transcription. These results show that palivizumab and motavizumab act at a point after F protein initiates interaction with the cell membrane and before virus transcription. Palivizumab and motavizumab also inhibited F protein-mediated cell-to-cell fusion. Therefore, these results strongly suggest that these antibodies block both cell-to-cell and virus-to-cell fusion, since these processes are likely similar. Finally, palivizumab and motavizumab did not reduce viral budding. Based on models developed from numerous studies of viral fusion proteins, our results indicate that these antibodies may prevent conformational changes in F protein required for the fusion process.Keywords
This publication has 49 references indexed in Scilit:
- Structural basis of respiratory syncytial virus neutralization by motavizumabNature Structural & Molecular Biology, 2010
- Structural and functional bases for broad-spectrum neutralization of avian and human influenza A virusesNature Structural & Molecular Biology, 2009
- Antibodies against viruses: passive and active immunizationCurrent Opinion in Immunology, 2008
- Overcoming T-Cell-Mediated Immunopathology to Achieve Safe Respiratory Syncytial Virus VaccinationFuture Virology, 2008
- Respiratory Syncytial Virus Infects and Abortively Replicates in the Lungs in Spite of Preexisting ImmunityJournal of Virology, 2007
- Structural basis of viral invasion: lessons from paramyxovirus FCurrent Opinion in Structural Biology, 2007
- Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory TractJournal of Molecular Biology, 2007
- Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme)Antiviral Research, 2006
- Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral NeutralizationJournal of Molecular Biology, 2005
- Electron Microscopy of the Human Respiratory Syncytial Virus Fusion Protein and Complexes That It Forms with Monoclonal AntibodiesVirology, 2000